Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
13.87
+0.25 (1.84%)
Sep 1, 2026, 10:59 AM EDT - Market open
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
265
Market Cap
11.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.66B |
| Bio-Techne | 1.22B |
| Ionis Pharmaceuticals | 874.09M |
| Corcept Therapeutics | 830.81M |
| Axsome Therapeutics | 776.57M |
| Arrowhead Pharmaceuticals | 669.50M |
| Krystal Biotech | 440.48M |
| Kymera Therapeutics | 105.00M |
SMMT News
- 6 days ago - Summit: Akeso reports ‘positive’ results from Phase III HARMONi-GI11 study - TheFly
- 6 days ago - Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China - Business Wire
- 7 days ago - Summit announces publication of primary analysis results from Phase III HARMONi - TheFly
- 7 days ago - Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology - Business Wire
- 7 days ago - Summit Therapeutics upgraded to Market Perform from Underperform at Bernstein - TheFly
- 15 days ago - Summit Therapeutics falls -8.5% - TheFly
- 15 days ago - Summit Therapeutics upgraded to Market Perform from Underperform at Leerink - TheFly
- 15 days ago - Summit says Akeso receives marketing authorization in China for ivonescimab - TheFly